Dominique T. Hussey
Dominique T. Hussey
Vice Chair and Toronto Managing Partner at Bennett Jones LLP
(416) 777-6230
(416) 863-1716
100 King St W, Suite 3400, 1 First Canadian Pl, PO Box 130, Toronto, ON
Year called to bar: 1999 (ON); 2003 (New York)
Dominique is Vice Chair & Toronto Managing Partner, co-leads the innovation, technology & branding practice, and heads the IP litigation group at Bennett Jones. Her practice involves all aspects of IP litigation and dispute resolution including patent, trademark, copyright, contracts, and trade secrets, with an emphasis on regulated products and life sciences, including extensive experience litigating under the Patented Medicines (Notice of Compliance) Regulations. In addition to counselling in all areas of IP and managing significant trademark portfolios, Dominique advises on advertising, marketing, packaging, labelling, and regulatory matters, most often pertaining to food, drugs, legal cannabis, cosmetics, and medical devices. Dominique also offers her experience to assist clients in navigating IP aspects of M&A and reorganization in a variety of regulated and retail industries. Dominique regularly writes, speaks, and teaches on written and oral advocacy, litigation, and intellectual property topics. She is admitted to practice in Ontario, the Federal Court of Canada, the United States District Courts for the Southern and Eastern Districts of New York, and the United States Court of Appeals for the Federal Circuit. She a member of the executive of the The Advocates’ Society.
Dominique T. Hussey is a featured Leading Lawyer in:
Canadian Legal Lexpert Directory
Most Frequently Recommended
Canadian Legal Lexpert Directory
Consistently Recommended
Dominique T. Hussey is also listed in the following publication(s)
Read more about Dominique T. Hussey in ...
Best intellectual property litigation lawyers in Ontario
Lexpert presents the best intellectual property litigation lawyers in Ontario based on the results of our comprehensive yearly peer survey
Concordia International Corp. (“Concordia” or the “Company”) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, completed the recapitalization of approximately US$4 billion of secured and unsecured debt in September 2018 pursuant to a plan of arrangement (the “CBCA Plan”) under the Canada Business Corporations Act (“CBCA”).